ACC.24 – Thoughts and Reflections
As the American College of Cardiology wrapped up its 73rd Annual Scientific Session in Atlanta, Georgia, the excitement surrounding the event was undeniable. With more than 17,000 attendees, ACC.24 proved to be a landmark event that showcased groundbreaking clinical advancements with immediate implications for cardiovascular practice. Held from April 6-8, 2024, at the Georgia World Congress Center, this year’s theme, “Advancing Cardiovascular Care for All,” underscored the collective mission to improve patient outcomes globally.
The comfortable spring temperatures in Atlanta provided an inviting atmosphere for dynamic exchanges both inside the conference halls and beyond. Attendees were treated to more than 20 trials featured in five late-breaking sessions, many of which are anticipated to reshape clinical practices. In addition to the cutting-edge trial results, the ACC celebrated the 40th Anniversary of the ACC/AHA Guidelines, with sessions focused on practical applications in areas such as atrial fibrillation, aortic disease, and valvular heart disease.
Medical Director,
Academic Interventional Cardiologist
Medical Director
At Medpace, we remain committed to shaping the future of cardiovascular care through our ongoing work with sponsors and research partners. Our team of cardiologists and clinical experts had the privilege of engaging with several key opinion leaders during and after the conference. In this interview series, we will share their reflections on pivotal data, the role of innovation in patient care, and the potential impact of these advancements on the field moving forward.
Q&As with Leading Cardiovascular Experts
In this series of expert insights, we are excited to feature discussions with renowned cardiovascular specialists who offer their perspectives on some of the most highly anticipated trials presented at ACC.24. Dr. Dean Kereiakes and Professor Thomas Pilgrim share their reflections on the DEDICATE trial, providing insights of the trial evaluating transcatheter aortic valve replacement or surgical aortic valve replacement in those with low or intermediate surgical risk. Dr. Salvatore Brugaletta and Professor Stefan James explore the findings of the PREVENT trial, which investigated the preventive use of percutaneous coronary intervention in non-flow-limiting vulnerable plaques. Professor Amitava Banerjee discusses the EMPACT-MI trial and its implications for using empagliflozin after acute myocardial infarction. Dr. Amir Kaki provides insights from the DanGer Shock trial, evaluating mechanical circulatory support in infarct-related cardiogenic shock, and Dr. Hany Ragy reviews the REDUCE-AMI trial, offering practical guidance for post-myocardial infarction patients with preserved ejection fraction.
These expert commentaries provide valuable clinical perspectives on how these trial findings may influence patient care and treatment strategies moving forward.
PREVENT:
Dr. Salvatore Brugaletta
Discover the key findings, which investigated the preventive use of percutaneous coronary intervention in non-flow-limiting vulnerable plaques.
PREVENT:
Prof. Stefan James
Professor James shares his takeaways from this multicenter, open-label, randomized controlled trial.
EMPACT-MI:
Prof. Amitava Banerjee
Learn more about the EMPACT-MI trial and its implications for using empagliflozin after acute myocardial infarction.
REDUCE-AMI:
Prof. Hany Ragy
Prof. Ragy offers practical guidance for post-myocardial infarction patients with preserved ejection fraction.
DEDICATE:
Dr. Dean Kereiakes
Dr. Kereiakes provides insights into this trial evaluating transcatheter or surgical aortic valve replacement in those with low or intermediate surgical risk.
DEDICATE:
Prof. Thomas Pilgrim
Prof. Pilgrim highlights the qualities that make a well-performing heart team in treating patients with structural heart disease.
DanGer Shock:
Dr. Amir Kaki
Learn more from this trial, evaluating mechanical circulatory support in infarct-related cardiogenic shock.
CARDIOVASCULAR cro
At Medpace, our team of cardiovascular specialists are highly skilled in the scientific methodology, standard of care, evolving regulatory requirements, and operational considerations to drive successful drug and device development for heart disease treatment. With tailored approaches and strong KOL relationships, we adapt to each trial’s unique requirements, ensuring precision and innovation throughout.